<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364377</url>
  </required_header>
  <id_info>
    <org_study_id>06-002673</org_study_id>
    <nct_id>NCT00364377</nct_id>
  </id_info>
  <brief_title>Incretins in Impaired Fasting Glucose</brief_title>
  <official_title>The Role of Incretins in the Pathogenesis of Fasting and Postprandial Glucose Metabolism in People With Impaired Fasting Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with high fasting glucose can develop type 2 diabetes with the passage of time. This
      study is being done to determine the effect of a novel medication in people with this
      elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally
      found in the blood. This hormone, called glucagon-like peptide-1 (GLP-1), is normally
      released by the intestine in response to the presence of food. This hormone acts like a
      messenger between the intestine and the pancreas to raise insulin levels, and therefore,
      lower blood sugars. Sitagliptin is effective in people with diabetes, however, this study is
      being done to determine if Sitagliptin is effective in people with high fasting glucose who
      do not yet have diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impaired fasting glucose (IFG) confers a high risk of progression to diabetes. Its
      pathogenesis has been an area of active investigation, with defects in insulin and glucagon
      secretion as well as insulin action likely to play a role. Several studies have suggested
      that the prediabetic and diabetic state are associated with alterations in circulating
      incretin concentrations. More recently, a large study of non-diabetic individuals
      demonstrated decreased GLP-1 concentrations after a glucose challenge in individuals with
      prediabetes but concluded that defects in GLP-1 secretion were unrelated to insulin
      secretion. In impaired glucose tolerance (IGT), defects in incretin-induced insulin secretion
      coexist with defects in glucose induced insulin secretion.

      Worsening degrees of glucose tolerance are associated with decreased insulin secretion for
      the prevailing insulin action. Moreover early glucagon suppression is impaired in IGT. Since
      GLP-1 is an insulin secretagogue and suppresses glucagon, it is conceivable that defects in
      GLP-1 secretion could contribute to the pathogenesis of pre-diabetes. Inhibition of
      Dipeptidyl Peptidase-4 (DPP-4), an enzyme which rapidly degrades the incretin hormones, has
      been shown to be a useful therapeutic strategy in type 2 diabetes. DPP-4 inhibitors increase
      (model-calculated) insulin secretion and decrease glucagon concentrations resulting in a
      lowering of fasting (and postprandial) glucose concentrations in people with type 2 diabetes.
      Their effects in people with IFG are less certain. However, DPP-4 inhibitors provide an
      opportunity to directly examine the contribution of abnormal incretin concentrations to the
      pathogenesis of IFG, by raising concentrations of endogenous incretin hormones.

      The current experiments tested this hypothesis by measuring insulin secretion and action and
      fasting and postprandial glucose turnover before and after 8 weeks of therapy with a DPP-4
      inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lowering of Fasting Glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>fasting glucose taken as the mean of blood glucose measured at -30, -20, -10 and 0 minutes prior to each inpatient meal study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>People with impaired fasting glucose randomized to treatment with placebo once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg once daily</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily for duration of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Twenty four participants aged 35 to 70 years with impaired fasting glucose (100mg/dl-125
        mg/dl) will be studied.

        Inclusion Criteria:

          -  Males and females between the ages of 35-70.

          -  Good health as determined by past medical history,physical examination, vital signs,
             electrocardiogram and laboratory tests at the time of screening.

          -  Patients on diuretics or thyroid hormone therapy must be on a stable dose (at least 3
             months prior to screening) and the maintenance dose may not be adjusted during the
             study.

        Exclusion Criteria:

          -  Individuals with a body mass index less than 19 or greater than 40 kg/m^2, or a total
             weight &gt; 130 kg, will be excluded from study.

          -  Subjects less than 35 years will not be studied in order to minimize the possibility
             of studying subjects with type 1 diabetes.

          -  No history of a) significant nephropathy, (i.e., plasma creatinine &gt; 1.4 mg/dl in
             women and 1.5 mg/dl in men, and/or proteinuria); b) clinically significant
             atherosclerotic vascular disease (e.g., history of heart attack or angina); c) a known
             systemic illness.

          -  Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf). 2010 Aug;73(2):189-96. doi: 10.1111/j.1365-2265.2009.03764.x. Epub 2009 Dec 18.</citation>
    <PMID>20039889</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>April 4, 2011</results_first_submitted>
  <results_first_submitted_qc>November 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2011</results_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Professor of medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Impaired Fasting Glucose (IFG) not on treatment with glucose-lowering medication</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>People with impaired fasting glucose treated with sitagliptin 100mg once daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>People with impaired fasting glucose treated with placebo once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>People with impaired fasting glucose treated with sitagliptin 100mg once daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>People with impaired fasting glucose treated with placebo once daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="2.5"/>
                    <measurement group_id="B2" value="54.1" spread="2.4"/>
                    <measurement group_id="B3" value="54.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lowering of Fasting Glucose</title>
        <description>fasting glucose taken as the mean of blood glucose measured at -30, -20, -10 and 0 minutes prior to each inpatient meal study</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis was per protocol - all participants completed the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>People with impaired fasting glucose treated with sitagliptin 100mg once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>People with impaired fasting glucose treated with placebo once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Lowering of Fasting Glucose</title>
          <description>fasting glucose taken as the mean of blood glucose measured at -30, -20, -10 and 0 minutes prior to each inpatient meal study</description>
          <population>Analysis was per protocol - all participants completed the intervention</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="0.12"/>
                    <measurement group_id="O2" value="5.83" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired comparisons (within groups) to examine differences between the baseline study and after 8-weeks of treatment were made using Student’s two-tailed t-test for paired samples. Between-group comparisons were made using Student’s two-tailed t-test for unpaired samples. Given the previously observed variation in fasting glucose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Twelve weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>People with impaired fasting glucose treated with sitagliptin 100mg once daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>People with impaired fasting glucose treated with placebo once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adrian Vella</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3754</phone>
      <email>vella.adrian@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

